INMUNE BIO INC. - COMM

INmune Bio Inc. Presents New Biomarker and Feasibility Data from Phase 1b Study Supporting the Use of XPro™ to Treat Alzheimer’s Disease at Clinical Trials on Alzheimer’s Disease (CTAD) Conference

17 أكتوبر 2023 07:00:00 بحسب Nasdaq GlobeNewswire

INmune Bio Inc. to Report Third Quarter 2023 Financial Results and Provide a Corporate Update on Wednesday, November 1

16 أكتوبر 2023 08:00:00 بحسب Nasdaq GlobeNewswire

INmune Bio Inc. to Present at Baird Global Healthcare Conference and H.C Wainwright 25th Annual Global Investment Conference

07 سبتمبر 2023 08:00:00 بحسب Nasdaq GlobeNewswire

INmune Bio Inc. Announces Approval of Clinical Trial Application by the U.K. Medicines and Healthcare Products Regulatory Agency for Phase 2 Clinical Trial in Alzheimer’s Disease

05 سبتمبر 2023 07:00:01 بحسب Nasdaq GlobeNewswire

INmune Bio Inc. Announces Second Quarter 2023 Results and Provides Business Update

07 أغسطس 2023 15:00:18 بحسب Nasdaq GlobeNewswire

INmune Bio Inc. to Present at the BTIG Virtual Biotechnology Conference

01 أغسطس 2023 07:00:01 بحسب Nasdaq GlobeNewswire

INmune Bio, Inc. to Report Second Quarter 2023 Financial Results and Provide a Corporate Update on Monday, August 7

31 يوليو 2023 07:00:00 بحسب Nasdaq GlobeNewswire

INmune Bio Inc. to Deliver Keynote Talk at 5th World Aging and Rejuvenation Conference.

12 يوليو 2023 07:00:00 بحسب Nasdaq GlobeNewswire

INmune Bio Inc. Announces Novel MRI Biomarker Data Demonstrating Improvement in Gray Matter in Patients with Alzheimer’s Disease

11 يوليو 2023 07:00:01 بحسب Nasdaq GlobeNewswire

INmune Bio Inc. Announces Data Presented at the 16th European Meeting on Glial Cells in Health and Disease Shows that XPro™ Promotes Remyelination by Affecting Astroglial and Microglial Biology

10 يوليو 2023 15:00:00 بحسب Nasdaq GlobeNewswire

INmune Bio Inc.’s Chief Scientific Officer, Mark Lowdell, Ph.D. to Present Plenary Talk at International Society of Cell & Gene Therapy

24 مايو 2023 08:00:01 بحسب Nasdaq GlobeNewswire

INmune Bio, Inc. Announces FDA Clearance of IND Application for INKmune™, a Natural Killer Therapy, for a Phase I/II Trial in Metastatic Castration-Resistant Prostate Cancer

08 مايو 2023 07:00:00 بحسب Nasdaq GlobeNewswire

INmune Bio Inc. Announces First Quarter 2023 Results and Provides Business Update

03 مايو 2023 15:10:51 بحسب Nasdaq GlobeNewswire

INmune Bio, Inc. to Report First Quarter 2023 Financial Results and Provide a Corporate Update on Wednesday, May 3

24 أبريل 2023 08:00:00 بحسب Nasdaq GlobeNewswire

XPro1595 Improves Outcomes in a Mouse Model of TBI-induced Alzheimer’s Disease

19 أبريل 2023 07:30:00 بحسب Nasdaq GlobeNewswire

INmune Bio, Inc. to Present Preclinical Data at the 2023 AACR Annual Meeting Showing Improved Outcomes in High-Risk Breast Cancer by Targeting MUC4 Expression with INB03

11 أبريل 2023 07:00:02 بحسب Nasdaq GlobeNewswire

INmune Bio, Inc. Announces Submission of Investigational New Drug (IND) Application for INKmune™ to the U.S. Food and Drug Administration for Treatment of Metastatic Castration-Resistant Prostate Cancer

03 أبريل 2023 08:00:00 بحسب Nasdaq GlobeNewswire

INmune Bio, Inc. Announces 2022 Results and Provides Business Update

02 مارس 2023 15:05:52 بحسب Nasdaq GlobeNewswire

INmune Bio, Inc. to Report Fourth Quarter and Full-Year 2022 Results and Provide a Corporate Update on Thursday, March 2

21 فبراير 2023 08:00:01 بحسب Nasdaq GlobeNewswire

INmune Bio, Inc. Receives Approximately $6.4 Million in Research and Development Rebates from Australia and the United Kingdom

08 فبراير 2023 07:45:00 بحسب Nasdaq GlobeNewswire